Health Condition 1: E119- Type 2 diabetes mellitus without complications
Conditions
Interventions
Intervention1: Satt-i Gilo capsule: 2 capsules of 500mg twice a day orally for a period of 90 days
Control Intervention1: Metformin: 1 Tablet of Metformin 500mg twice a day orally for a period of 90 d
Sponsors
Luqman Unani Medical College Hospital and Research Center
Eligibility
Inclusion criteria
Inclusion criteria: 1-Diagnosed cases of type 2 Diabetes mellitus with blood sugar level: -Fasting blood sugar equal to or more than 126mg/dl to more than 200mg/dl, -Random or post-prandial blood sugar level equal to or more than 200mg/dl to more than 300mg/dl, and -HbA1c equal to or more than 6.5% to 8% 2-Patient ready to participate in the study and ready to follow instructions
Exclusion criteria
Exclusion criteria: -Diagnosed cases of type 2 DM with Fasting blood sugar more than 200mg/dl, Random OR Postprandial blood sugar more than 300mg/dl, and HbA1c more than 8 percent -Patient of type 1 Diabetes mellitus on insulin. -Cases of gestational diabetes mellitus. -Pregnant and lactating women. -Patient with complications like nephropathy, neuropathy, retinopathy, ketoacidosis, lactic acidosis. -Known cases of CAD, PVD, Stroke, liver diseases, hemoglobinopathy, and accelerated hypertension.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -HbA1c (Glycosylated hemoglobin) -eAG (Estimated average glucose)Timepoint: At baseline and after 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| -Fasting blood sugar -Postprandial blood sugar -Diabetes quality of life(DQoL)Timepoint: At baseline, 30 days, 60 days and after completion of study | — |
Countries
India
Contacts
Public ContactMohd Khalid
Luqman Unani Medical College Hospital and Research Center
Outcome results
None listed